ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study-Reference-Cited by-同舟云学术

ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study

Published:2020-09-11 Issue:24 Volume:126 Page:5303-5310
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Geller James I.¹^ORCID,Pressey Joseph G.¹,Smith Malcolm A.²^ORCID,Kudgus Rachel A.³,Cajaiba Mariana⁴,Reid Joel M.³,Hall David⁵,Barkauskas Donald A.⁶,Voss Stephen D.⁷,Cho Steve Y.⁸,Berg Stacey L.⁹,Dome Jeffrey S.¹⁰,Fox Elizabeth¹¹,Weigel Brenda J.¹²

Affiliation:

1. Division of Oncology Cincinnati Children's Hospital Medical Center, University of Cincinnati Cincinnati Ohio

2. Cancer Therapy Evaluation Program National Institutes of Health Bethesda Maryland

3. Mayo Clinic Comprehensive Cancer Center Rochester Minnesota

4. Lurie Children's Hospital of Chicago Chicago Illinois

5. Children's Oncology Group Monrovia California

6. Keck School of Medicine, University of Southern California Los Angeles California

7. Dana‐Farber Cancer Institute Boston Massachusetts

8. University of Wisconsin Hospital and Clinics Madison Wisconsin

9. Dan L. Duncan Comprehensive Cancer Center Baylor College of Medicine Houston Texas

10. Children's National Medical Center Washington DC

11. Children's Hospital of Philadelphia Philadelphia Pennsylvania